First National Equities Limited · PSX:FNEL
First National Equities — Investor Presentation (November 2025)
20 slides from First National Equities's investor presentation, November 2025
Slide 1: First National Equities Limited
_—_ FIRST NATIONAL EQUITIES LIMITED
Slide 2: Vision, Mission and Philosophy
VISION “Connecting people, ideas and capital, we will be our client’s first choice for achieving their financial aspirations”. MISSION “We put interest of our stakeholders above our own; and measure our success by how much we help them in achieving theirs”. PHILOSOPHY Business @ Speed of Thought
Slide 3: Board of Directors
Board of Directors Mr. Adnan Amjad Khan, Director & Chairman Mr. Amir Shehzad, Director & Acting CEO Mr. Muhammad Bilal, Director Mr. Waseem Ahmad Khan, Director Mr. Muhammad Umair Khan, Director Ms. Mavra Liaqat, Director Ms. Ayesha Afzal, Director
Slide 4: Management
MANAGEMENT Mr. Amir Shehzad (Acting CEO) Mr. Mavra Liaqat (Company Secretary & Acting CFO)
Slide 5: Company Introduction
COMPANY INTRODUCTION FNEL was incorporated in February, 1995. FNEL was listed on Karachi Stock Exchange as Public Limited Company in 2004. FNEL is engaged in the business of Brokerage and Portfolio Management. FNEL was awarded the Top Companies Award by Karachi Stock Exchange Limited in 2006
Slide 6: Financial Details
Financial Details Cement ponion of log-term Gancing, ‘ronan find pupae “Total Libis awingecis an comments Net Assets [REPRESENTED BY: Autonaed shar etl Ae, secre and pid-p share capil ‘isco on sight shares Accumulated ie nea gin on re measrement of vem oa aoR ‘The annexed notes from Ito 43 foem an i
Slide 7: Financial Details
Financial Details [FIRST NATIONAL EQUITIES LIMITED STATEMENT OF PROFIT OR LOSS FOR THE YEAR ENDED JUNE 30, 2025 a Opeting noes 2 ssonase ie Lim) ona finest SSS Ural gion) on mew oats prea 7g ars et ma (4,385,264) Operating rot ame Adenine eapemes a Maas, ince cot a oe er peng epeeee ot ee te pein nc
Slide 8: Financial Details
Financial Details FIRST NATIONAL EQUITIES LIMITED STATEMENT OF COMPREHENSIVE INCOME, FOR THE YEAR ENDED JUNE 30, 2125 ceaeenrllupertnemnnne Loe afc income Gtarze6n tems that will ot be reclatsifed subsequently to prot oF lose Unrealized gain during the year inthe mark value of westments ase at fe va
Slide 9: FNEL: Advancing Into a High-Growth Future
FNEL: Advancing Into a High- Growth Future FNEL is undergoing a strategic transformation aimed at repositioning the Company as a high-growth, Sharia- compliant enterprise anchored in pharmaceutical manufacturing and technology enablement. This shift reflects the Board’s long-term view: move decisive
Slide 10: Strategic Realignment: Exiting Legacy Brokerage & Investments
Strategic Realignment: Exiting Legacy Brokerage & Investments A Deliberate and Accelerated Transition FNEL has initiated a structured plan to scale down and ultimately exit its traditional brokerage and investment businesses. This transition aligns the Company with industries that offer: • Stronger
Slide 11: Sector Reclassification: Transitioning From Brokerage to Pharmaceuticals
Sector Reclassification: Transitioning From Brokerage to Pharmaceuticals To reflect its evolving business model, FNEL is also actively pursuing a change in its sector classification, moving away from the brokerage and investment category and aligning itself with the pharmaceuticals and healthcare se
Slide 12: Kingbhai Digisol: Capital Raise to Unlock Multi-Million Dollar Valuation
Kingbhai Digisol: Capital Raise to Unlock Multi-Million Dollar Valuation Strategic Funding to Accelerate FNEL’s Pivot Toward Pharma The Company has commenced work on a formal capital-raising process for its technology subsidiary, Kingbhai Digisol. Key dynamics: • FNEL is evaluating all capital-raisi
Slide 13: Albert Pharma Acquisition: Anchoring the Pharmaceutical Platform
Albert Pharma Acquisition: Anchoring the Pharmaceutical Platform A Fully Regulated, Commercially Active Pharmaceutical Operation FNEL’s proposed acquisition of Albert Pharma (Private) Limited signals a decisive and long-term commitment to the pharmaceutical sector. Albert Pharma – Core Strengths • O
Slide 14: Pharmaceutical Strategy: Building a Scalable Growth Engine
Pharmaceutical Strategy: Building a Scalable Growth Engine FNEL’s multi-year pharmaceutical roadmap is centered on: • Expansion of therapeutic product lines • Increased manufacturing capacity • Deeper penetration across Pakistan’s major urban and semi-urban markets • Strategic entry into export mark
Slide 15: Sharia Compliance Transformation
Sharia Compliance Transformation FNEL is committed to transitioning into a fully Sharia-compliant corporate structure across: • Financing • Investments • Operating models This realignment positions the Company to access broader capital pools, enhance governance, and deliver long-term, asset- backed,
Slide 16: Real Estate Investment Portfolio Under Strategic Review
Real Estate Investment Portfolio Under Strategic Review FNEL is conducting a comprehensive assessment of its real estate holdings to ensure optimal capital allocation. The Company’s priority is to deploy capital into higher-growth, cash- generating verticals, primarily pharmaceuticals and technology
Slide 17: FY 2026 Earnings Guidance: Strengthening Financial Performance
FY 2026 Earnings Guidance: Strengthening Financial Performance FNEL is providing its forward earnings outlook for FY 2026 based on improved operational visibility and the expected contribution from new business verticals. Earnings Guidance for FY 2026 • Full-Year EPS projected to exceed PKR 4.00 • K
Slide 18: Forward-Looking Outlook
Forward-Looking Outlook FNEL is positioned for a significant multi-year transformation, driven by: • Rapid exit from legacy brokerage operations • Formal sector reclassification toward pharmaceuticals • Value unlocking through a multi-million- dollar capital raise for Kingbhai Digisol • Acquisition
Slide 19: FNEL: Evolving Into a High-Value, Multi-Sector Growth Company
FNEL: Evolving Into a High-Value, Multi-Sector Growth Company FNEL is building a new corporate identity: A Sharia-compliant, pharma-centric, technology-enabled, growth-focused company with a clear roadmap to sustained value creation.
Slide 20: Thank You
First National Equities — Investor Presentation (November 2025) on 6ix